Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 booster study of WSK-V101C bivalent XBB + prototype COVID-19 protein vaccine in adults
ChiCTR2300073056Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of Recombinant COVID-19 bivalent xbb+prototype protein vaccine and WSK-V101 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Incidence of adverse events and adverse reactions 0 to 7 days after vaccination and Neutralizing antibody GMT and seroconversion against current circulating SARS-CoV-2 variants. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
Recombinant COVID-19 bivalent xbb+prototype protein vaccineWSK-V101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300073056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073056.